Literature DB >> 26133668

The angiotensin receptor blocker losartan reduces coronary arteriole remodeling in type 2 diabetic mice.

Kathryn E Husarek1, Paige S Katz2, Aaron J Trask3, Maarten L Galantowicz4, Mary J Cismowski4, Pamela A Lucchesi5.   

Abstract

Cardiovascular complications are a leading cause of morbidity and mortality in type 2 diabetes mellitus (T2DM) and are associated with alterations of blood vessel structure and function. Although endothelial dysfunction and aortic stiffness have been documented, little is known about the effects of T2DM on coronary microvascular structural remodeling. The renin-angiotensin-aldosterone system plays an important role in large artery stiffness and mesenteric vessel remodeling in hypertension and T2DM. The goal of this study was to determine whether the blockade of AT1R signaling dictates vascular smooth muscle growth that partially underlies coronary arteriole remodeling in T2DM. Control and db/db mice were given AT1R blocker losartan via drinking water for 4 weeks. Using pressure myography, we found that coronary arterioles from 16-week db/db mice undergo inward hypertrophic remodeling due to increased wall thickness and wall-to-lumen ratio with a decreased lumen diameter. This remodeling was accompanied by decreased elastic modulus (decreased stiffness). Losartan treatment decreased wall thickness, wall-to-lumen ratio, and coronary arteriole cell number in db/db mice. Losartan treatment did not affect incremental elastic modulus. However, losartan improved coronary flow reserve. Our data suggest that Ang II-AT1R signaling mediates, at least in part, coronary arteriole inward hypertrophic remodeling in T2DM without affecting vascular mechanics, further suggesting that targeting the coronary microvasculature in T2DM may help reduce cardiac ischemic events.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Angiotensin receptor blocker; Coronary arterioles; Type 2 diabetes mellitus; Vascular remodeling

Mesh:

Substances:

Year:  2015        PMID: 26133668      PMCID: PMC5592725          DOI: 10.1016/j.vph.2015.06.013

Source DB:  PubMed          Journal:  Vascul Pharmacol        ISSN: 1537-1891            Impact factor:   5.773


  51 in total

Review 1.  Exercise is the real polypill.

Authors:  Carmen Fiuza-Luces; Nuria Garatachea; Nathan A Berger; Alejandro Lucia
Journal:  Physiology (Bethesda)       Date:  2013-09

2.  Differential effects of angiotensin II on cardiac cell proliferation and intramyocardial perivascular fibrosis in vivo.

Authors:  P E McEwan; G A Gray; L Sherry; D J Webb; C J Kenyon
Journal:  Circulation       Date:  1998-12-15       Impact factor: 29.690

3.  Angiotensin II plays a critical role in diabetic pulmonary fibrosis most likely via activation of NADPH oxidase-mediated nitrosative damage.

Authors:  Junling Yang; Yi Tan; Fenglian Zhao; Zhongsen Ma; Yuehui Wang; Shirong Zheng; Paul N Epstein; Jerry Yu; Xia Yin; Yang Zheng; Xiaokun Li; Lining Miao; Lu Cai
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-04-12       Impact factor: 4.310

4.  Coronary and aortic endothelial function affected by feedback between adiponectin and tumor necrosis factor α in type 2 diabetic mice.

Authors:  Hanrui Zhang; Yoonjung Park; Cuihua Zhang
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-09-02       Impact factor: 8.311

5.  Coronary arterioles in type 2 diabetic (db/db) mice undergo a distinct pattern of remodeling associated with decreased vessel stiffness.

Authors:  Paige S Katz; Aaron J Trask; Flavia M Souza-Smith; Kirk R Hutchinson; Maarten L Galantowicz; Kevin C Lord; James A Stewart; Mary J Cismowski; Kurt J Varner; Pamela A Lucchesi
Journal:  Basic Res Cardiol       Date:  2011-07-10       Impact factor: 17.165

6.  Compromised renal microvascular reactivity of angiotensin type 1 double null mice.

Authors:  Sungmi Park; Benjamin J Bivona; Lisa M Harrison-Bernard
Journal:  Am J Physiol Renal Physiol       Date:  2007-04-04

7.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

Authors: 
Journal:  Lancet       Date:  2000-01-22       Impact factor: 79.321

8.  Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Lars H Lindholm; Hans Ibsen; Björn Dahlöf; Richard B Devereux; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Krister Kristiansson; Ole Lederballe-Pedersen; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Peter Aurup; Jonathan Edelman; Steven Snapinn
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

Review 9.  Interactions between microvascular and macrovascular disease in diabetes: pathophysiology and therapeutic implications.

Authors:  Andrew J Krentz; Geraldine Clough; Christopher D Byrne
Journal:  Diabetes Obes Metab       Date:  2007-11       Impact factor: 6.577

Review 10.  Growth factors and the development of diabetic nephropathy.

Authors:  Gunter Wolf
Journal:  Curr Diab Rep       Date:  2003-12       Impact factor: 5.430

View more
  7 in total

1.  Reduced stiffness and augmented traction force in type 2 diabetic coronary microvascular smooth muscle.

Authors:  Patricia E McCallinhart; Youjin Cho; Zhe Sun; Samir Ghadiali; Gerald A Meininger; Aaron J Trask
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-05-01       Impact factor: 4.733

Review 2.  Coronary microvascular disease as an early culprit in the pathophysiology of diabetes and metabolic syndrome.

Authors:  Hicham Labazi; Aaron J Trask
Journal:  Pharmacol Res       Date:  2017-07-09       Impact factor: 7.658

3.  Isolation of Murine Coronary Vascular Smooth Muscle Cells.

Authors:  Kathryn E Husarek; Xiaojin Zhang; Patricia E McCallinhart; Pamela A Lucchesi; Aaron J Trask
Journal:  J Vis Exp       Date:  2016-05-30       Impact factor: 1.355

Review 4.  Coronary remodeling and biomechanics: Are we going with the flow in 2020?

Authors:  Patricia E McCallinhart; Benjamin W Scandling; Aaron J Trask
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-11-13       Impact factor: 4.733

5.  Experimental animal models of coronary microvascular dysfunction.

Authors:  Oana Sorop; Jens van de Wouw; Selena Chandler; Vahagn Ohanyan; Johnathan D Tune; William M Chilian; Daphne Merkus; Shawn B Bender; Dirk J Duncker
Journal:  Cardiovasc Res       Date:  2020-03-01       Impact factor: 10.787

6.  Improvement of automated analysis of coronary Doppler echocardiograms.

Authors:  Christopher W Bartlett; William C Ray; Aaron J Trask; Jamie Bossenbroek; Yukie Ueyama; Patricia E McCallinhart
Journal:  Sci Rep       Date:  2022-05-06       Impact factor: 4.996

7.  Overexpression of p53 due to excess protein O-GlcNAcylation is associated with coronary microvascular disease in type 2 diabetes.

Authors:  Rui Si; Qian Zhang; Atsumi Tsuji-Hosokawa; Makiko Watanabe; Conor Willson; Ning Lai; Jian Wang; Anzhi Dai; Brian T Scott; Wolfgang H Dillmann; Jason X-J Yuan; Ayako Makino
Journal:  Cardiovasc Res       Date:  2020-05-01       Impact factor: 10.787

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.